3M Company (MMM) — 2023 Form 10-K
Business context and reporting period. This is 3M’s annual report for the fiscal year ended December 31, 2023, filed February 7, 2024. 3M is a diversified global manufacturer reporting four segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The filing provides full-year results; it does not provide clear standalone fourth-quarter financial values in the supplied text.
Financial performance
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net sales | $32.681 billion | $34.229 billion |
| Worldwide sales change | (4.5)% | (3.2)% |
| Operating income (loss) | $(9.128) billion | $6.539 billion |
| Net income (loss) attributable to 3M | $(6.995) billion | $5.777 billion |
| Diluted EPS | $(12.63) | $10.18 |
| Operating cash flow | $6.680 billion | $5.591 billion |
| Capital expenditures | $1.615 billion | $1.749 billion |
| Free cash flow (non-GAAP) | $5.065 billion | $3.842 billion |
GAAP results were heavily affected by significant litigation costs. 3M recorded approximately $15.2 billion of pre-tax net costs for significant litigation in 2023, including charges associated with the public water systems (PWS) and Combat Arms Earplugs (CAE) settlements. Excluding special items, 3M reported non-GAAP sales of $31.392 billion, operating income of $6.388 billion, operating margin of 20.3%, net income of $5.122 billion, and diluted EPS of $9.24. These non-GAAP measures exclude specified special items and are not substitutes for GAAP results.
Margins and segments. GAAP operating margin was (27.9)%, versus 19.1% in 2022, primarily reflecting litigation charges; the non-GAAP adjusted margin was 20.3%, versus 21.1%. Sales declined across all four segments: Safety and Industrial $10.956 billion (down 5.6%); Transportation and Electronics $8.501 billion (down 4.5%); Health Care $8.195 billion (down 2.8%); and Consumer $5.026 billion (down 5.0%). Sales weakness included lower disposable respirator demand, softness in consumer electronics and consumer retail, and declines in China. Health Care operating income also faced costs associated with preparing for the planned spin-off.
Cash, debt and liquidity. Cash, cash equivalents and marketable securities totaled $6.006 billion at year-end, up from $3.916 billion. Total debt was $16.035 billion, compared with $15.939 billion; reported net debt (non-GAAP) fell to $10.029 billion from $12.023 billion. Cash and marketable securities included approximately $3.2 billion held outside the United States. Working capital was $1.082 billion, down from $5.165 billion, largely because current liabilities increased with settlement obligations. 3M had $1.795 billion of commercial paper outstanding and an undrawn $4.25 billion revolving credit facility. Its facility covenant EBITDA-to-interest ratio was approximately 15:1 against a 3:1 minimum.
Material changes versus 2022
- Sales declined 4.5%; organic sales decreased 3.2%, with foreign exchange and divestitures also affecting reported sales.
- GAAP earnings shifted from profit to loss, principally because of the PWS and CAE settlement charges. Adjusted diluted EPS decreased to $9.24 from $9.88.
- Operating cash flow rose by $1.089 billion, aided in part by inventory reductions; capital spending declined by $134 million.
- 3M repurchased $33 million of stock in 2023, versus $1.5 billion in 2022. Dividends declared and paid totaled $6.00 per share, versus $5.96.
- Headcount fell to approximately 85,000 from 92,000. The company recorded $437 million in 2023 restructuring charges.
Outlook, litigation and other notable items
- Health Care separation: 3M expected to complete the planned spin-off in the first half of 2024, subject to customary conditions and approvals. It expected initially to retain a 19.9% ownership interest. The filing does not provide a guaranteed completion date or confirmed final transaction terms.
- PFAS: 3M plans to exit all PFAS manufacturing and work to discontinue PFAS use across its product portfolio by the end of 2025. The company cited supply substitution, regulatory, operational, customer and cost uncertainties. PFAS-related obligations and regulatory matters remain significant.
- PWS settlement: The proposed settlement provides for $10.5 billion to $12.5 billion of payments from 2023 through 2036, subject to court approval and other conditions. Preliminary approval was granted in 2023; the final approval hearing was held February 2, 2024. The supplied filing text does not state the hearing’s outcome.
- CAE settlement: 3M agreed to contribute $6.0 billion between 2023 and 2029, subject to participation conditions including a 98% claimant enrollment threshold. In January 2024, 3M irrevocably elected to pay the settlement’s $1 billion portion that could have been paid in stock in cash.
- Restructuring and investment: The 2023–2025 structural reorganization is expected to affect approximately 8,500 positions and incur $700 million to $900 million in pre-tax charges. 3M forecast 2024 capital spending of approximately $1.5 billion to $1.7 billion and global defined-benefit pension and postretirement contributions of $100 million to $200 million. No clear formal 2024 revenue or EPS guidance is provided in the supplied text.
- Environmental spending: 3M spent approximately $316 million on environmental capital projects in 2023 and expected approximately $365 million in aggregate for 2024 and 2025. It recorded $11.0 billion in PFAS-related other environmental liabilities at year-end and said potential losses above established accruals could not be estimated.
- Credit and market risks: Ratings at the report date included Moody’s A3 with negative outlook and S&P BBB+ with CreditWatch negative; Fitch rated 3M A- with stable outlook. The company highlighted litigation, PFAS regulation, the Health Care spin-off, restructuring execution, demand, inflation, currency, supply chains, cybersecurity and pension assumptions as risks.
Investor verification priorities
- Check the court’s final disposition of the PWS settlement, opt-out levels, payment schedule and any effect on other PFAS claims.
- Track CAE claimant participation against the settlement threshold, actual cash payments and any nonparticipating or future claims.
- Verify progress and costs of the PFAS exit, including availability of substitutes and the status of permits and operations at the Zwijndrecht, Belgium facility.
- Confirm the Health Care spin-off’s approvals, financing, timing, retained ownership and expected separation costs or dis-synergies.
- Monitor settlement cash outflows, debt and credit ratings alongside operating cash generation and planned capital spending.